The Life Science industry is in a state of flux. While recent years have seen the advent of multiple novel technologies—such as IVF, CRISPR-Cas9, virtual clinical trials, and liquid biopsy—the industry today stands at a crossroads with challenges in scaling up and commercializing such technologies. The industry has now come to terms with new, path-breaking life science technologies that are helping make precision healthcare a reality. Chinese investments into the US biopharma industry jumped to $4.5 billion in 2018. An exclusive fireside chat with our US and China analysts will uncover trends in cross-border investments and growth opportunities in these two markets.
Date: Wednesday, February 6, 2019
Time: 11:00 AM EST
To submit a question that will be answered live during
the briefing, please email it to Gil_Briefings@frost.com.